Open Orphan #ORPH – Exec Chairman Cathal Friel & Non Exec Director Prof. Brendan Buckley purchase shares
The Company announces that it has received notification that, on 14 July 2021, Cathal Friel, Executive Chairman of the Company, purchased 1,132,075 ordinary shares of 0.1 pence each in the capital of the Company (“Shares”) at a price of 26.5 pence per Share and that Prof. Brendan Buckley, Non-Executive Director of the Company, purchased 188,679 […]
Open Orphan (ORPH) Appoints Professor Oxford as Chair of Advisory Board, with initial focus to help guide Open Orphan in the provision of solutions to Coronavirus outbreak
Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce the appointment of Professor […]
Open Orphan Plc (ORPH) Directorate Changes
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director. David has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics […]